Please login to the form below

Not currently logged in
Email:
Password:

Cancer drug, Oxaliplatin, approved for UK

Colon and rectum cancer drug, Oxaliplatin, has been approved for use in the UK

Onco Therapies Ltd (OTL), a subsidiary of Strides Arcolab, has announced that its colon and rectum cancer drug, Oxaliplatin, has been approved through a decentralised procedure for use in the UK. Approval across other European countries is expected shortly.

The drug will be manufactured at Strides' oncology complex in Bangalore, India, and used to treat advanced cancer of the colon and rectum in combination with other medicines to slow or stop cancer cell growth. It will be administered as a 5mg/ml injection.

Oxaliplatin is one of 37 drugs licensed to Pfizer on a semi-exclusive basis for sales in 17 European countries.

This is the second European approval out of 22 filings made by the OTL in 2010, for products with a combined market value of over $5bn.

15th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics